CDEK
← All drugs Report issue

sarpogrelate

Small moleculeexperimental

Sarpogrelate is a drug which acts as an antagonist at the serotonin 5-HT2A 5-HT2B, and 5-HT2C receptors. However, its affinities for the human 5-HT2C and 5-HT2B receptors are about one and two orders of magnitude lower than for the human 5-HT2A receptor, respectively. The drug blocks serotonin-induced platelet aggregation, and has potential applications in the treatment of many diseases including diabetes mellitus, Buerger's disease, Raynaud's disease, coronary artery disease, angina pectoris, and atherosclerosis. — Wikipedia

Clinical trial activity

20 trials · 12 clinical orgs · 0 marketing orgs

Phase 1
8
Phase 2
4
Phase 3
4
Phase 4
7

Earliest trial started Jan 1, 2001 (NCT00129805)

Timeline

2000s

  1. Jan 1, 2001

    Earliest Phase 3 Sponsor(trial)

2010s

  1. Jan 1, 2011

    Earliest Phase 1 Sponsor(trial)

Indications

Approved for

Studied for

Mechanism of action

Chemistry & pharmacology

Loading structure…

SMILES

COc1cccc(CCc2ccccc2OCC(CN(C)C)OC(=O)CCC(=O)O)c1
Mol. weight
429.51 g/mol
Lipinski Ro5
Pass
Rule of 3
No
Chirality
Racemic Mixture
Inorganic
No
Polymer
No

Oral

No

Parenteral

No

Topical

No

Sources

Also known as

  • 2-(dimethylamino)-1-((2-(3-methoxyphenyl)phenoxy)methyl)ethyl hydrogensuccinate hydrochloride
  • anplag
  • anplag
  • anplag
  • anplag
  • dp-r202
  • mci 9042
  • mci-9042
  • mci-9042
  • mci-9042
  • mci-9042
  • mono-(2-(dimethylamino)-1-((2-(2-(3-methoxyphenyl)ethyl)phenoxy)methyl)ethyl)succinate hydrochloride
  • sarpogrelate
  • sarpogrelate
  • sarpogrelate
  • sarpogrelate
  • sarpogrelate
  • sarpogrelate
  • sarpogrelate
  • sarpogrelate hcl
  • sarpogrelate hcl
  • sarpogrelate hcl
  • sarpogrelate hydrochloride
  • sarpogrelate hydrochloride

Clinical trials

NCT IDPhaseStart dateSponsor(s)
NCT05730621Phase 4Jan 11, 2023Yuhan Pharmaceutical Company
NCT03947528Phase 1Mar 4, 2019Daewoong Pharmaceutical Co. LTD.
NCT03947489Phase 1Mar 4, 2019Daewoong Pharmaceutical Co. LTD.
NCT03509922Phase 4Jun 30, 2018Yuhan Pharmaceutical Company
NCT03574285Phase 1May 31, 2018Daewoong Pharmaceutical Co. LTD.
NCT03573622Phase 1May 31, 2018Daewoong Pharmaceutical Co. LTD.
NCT02959606Phase 4Nov 1, 2016Seoul National University
NCT02607436Phase 4Jul 1, 2015Seoul National University
NCT02097511Phase 1Dec 1, 2013Ajou University
NCT01869881Phase 4Feb 1, 2013Korea University, Yuhan Pharmaceutical Company
NCT02393612Phase 3Oct 1, 2012Alvogen
NCT01674686Phase 4Aug 1, 2012Sungkyunkwan University
NCT01841086Phase 1Sep 1, 2011Korea United Pharm. Inc., Sungkyunkwan University
NCT01429688Phase 1Jul 1, 2011Alvogen, Sungkyunkwan University
NCT01421563Phase 1Feb 1, 2011Alvogen, Sungkyunkwan University
NCT01548274N/AOct 1, 2010Aichi Gakuin University
NCT01165567Phase 4Dec 1, 2009Seoul National University
NCT02294643Phase 3Apr 1, 2009Seoul National University, Yuhan Pharmaceutical Company
NCT00147303Phase 3Apr 1, 2004Mitsubishi Tanabe, Tokyo Women's Medical University
NCT00129805Phase 3Jan 1, 2001Federation of National Public Service Personnel Mutual Aid Associations Tachikawa Hospital, Mitsubishi Tanabe
Showing 20 of 20 trials
Page 1 / 1

Organizations

Research & Development (12)

OrganizationOrg typeTrialsAs lead sponsorPhasesEarliest year
Daewoong Pharmaceutical Co. LTD.For profit4412018
Seoul National UniversityAcademic/Hospital4422009
Sungkyunkwan UniversityAcademic/Hospital4122011
Yuhan Pharmaceutical CompanyFor profit4322009
AlvogenFor profit3322011
Mitsubishi TanabeFor profit2212001
Aichi Gakuin UniversityAcademic/Hospital1112010
Ajou UniversityAcademic/Hospital1112013
Federation of National Public Service Personnel Mutual Aid Associations Tachikawa HospitalAcademic/Hospital1012001
Korea United Pharm. Inc.For profit1112011
Korea UniversityAcademic/Hospital1012013
Tokyo Women's Medical UniversityAcademic/Hospital1012004
12 organizations
Page 1 / 1